Erratum
for
Heymach et al., J Clin Oncol 25 (27) 4270-4277.
Journal of Clinical Oncology, Vol 26, No 1 (January 1), 2008: pp. 165-166
© 2008 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2007.15.0789
ERRATA
The September 20, 2007 article by Heymach et al entitled, "Randomized, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer" (J Clin Oncol 25:4270-4277, 2007) contained errors.
In Figure 1, under "Run-in phase," the dosage for Vandetanib in the second box was given as 100 mg, whereas it should have been 300 mg. Corrected Figure 1 is reprinted below in its entirety.
In Table 1, the call out for the second footnote ( ) was given next to the row for "IIIB," whereas it should have appeared next to the row for "Stage." Also, the second footnote referred to two patients, whereas it should only have been one, as follows:
Data not available for one patient in the vandetanib 100 mg + docetaxel arm.
The online version has been corrected in departure from the print.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
|
